Welcome Message from Dr. Walter J. Koroshetz

Welcome to the “Alzheimer’s Disease-Related Dementias (ADRD) Summit 2019.” Together with the National Institute on Aging’s Alzheimer’s Disease Research Summits in 2012, 2015, 2018, the National Research Summit on Care, Services, & Supports for Persons with Dementia and their Caregivers in 2017 and the NINDS-led ADRD Summits in 2013 and 2016, the ADRD Summit responds to the National Alzheimer’s Project Act (NAPA) signed into law in 2011. As in previous summits, the goal of the ADRD Summit 2019 is to solicit input from internationally recognized experts and to develop prioritized recommendations to guide scientific research during the next 5 to 10 years. In addition, the Summit will report progress on the research recommendations set by the 2016 ADRD Summit and will revise those recommendations based on scientific advances over the last 3 years. The group assembled will focus on frontotemporal degeneration, Lewy body, and vascular contributions to cognitive impairment and dementia both alone and in combination with Alzheimer’s disease biology. Discussion will also focus on the associated diagnostic challenges, dementia nomenclature, issues related to health disparities, and emerging scientific topics, including TDP-43 pathology, and TBI in dementia, as we pursue a better scientific understanding of these various types of dementia.

On behalf of the National Institute of Neurological Disorders and Stroke (NINDS), I’d like to thank the many people who helped to make the Summit possible, including Julie Schneider, the Scientific Chair, and the Session Chairs: Lisa Barnes, Brad Boeve, Adam Boxer, Kristen Dams-O’Connor, Hector Gonzalez, David Knopman, Carol Lippa, Ron Petersen, Len Petrucelli, Kate Possin, Angela Taylor, Donna Wilcock, and Jeff Williamson. I also want to thank the leadership and staff of the National Institute on Aging, whose assistance has been invaluable, as well as others who helped support this event.

We appreciate your active participation in the Summit, which will include many opportunities for public questions and comment. With your input, we hope to make a significant contribution to the National Plan’s goal to prevent and effectively treat Alzheimer’s disease and Alzheimer’s disease-related dementias by 2025.
Sponsored by the
National Institutes of Neurological Disorders and Stroke

In partnership with:
National Institute on Aging

With additional support from:
National Institutes of Health Office of Disease Prevention
Foundation of the National Institutes of Health

And special thanks for assistance with outreach:
Alzheimer’s Association
LEAD Coalition (Leaders Engaged on Alzheimer’s Disease)
Lewy Body Dementia Association
The Association for Frontotemporal Degeneration

About our cover:
Program cover images highlight task-free fMRI data linking patterns of neurodegeneration to interconnected brain systems, one for each dementia subtype. In corticobasal syndrome, a subtype of FTD, the target network “epicenters” are found in the perirolandic cortex (as shown). Images provided courtesy of Dr. William Seeley. For further information see Zhou et al., Neuron, 2012: 1216-27.
Agenda

Thursday, March 14, 2019

7:00 a.m.  Registration

INTRODUCTION

8:00 a.m.  Welcoming Remarks and Introduction
           Walter Koroshetz, MD, Director, National Institute of Neurological Disorders and Stroke

8:10 a.m.  Perspective
           Laura Gitlin, MD, PhD, Chair, Advisory Council on Alzheimer’s Research, Care, and Services

8:20 a.m.  Progress and Updating Research Recommendations for the Alzheimer’s Disease-Related Dementias
           Julie Schneider, MD, MS, Scientific Chair, and Roderick Corriveau, PhD, NIH Lead, ADRD Summit 2019, National Institute of Neurological Disorders and Stroke

SESSION 1: Multiple Etiology Dementias – Diagnosing Dementia in the 21st Century
   Chairs: David Knopman, MD, and Kate Possin, PhD

8:40 a.m.  Session Introduction – Revised Recommendations: Reconciling the Gap between Aspirational and Operational Goals
           David Knopman, MD

8:47 a.m.  Recommendation 3: Advance Basic and Clinical Research in MED
           David Knopman, MD

8:59 a.m.  Recommendations 1 and 2: Progress and Next Steps in Detection and Diagnosis of Cognitive Impairment and Dementia
           Kate Possin, PhD and Alireza Atri, MD, PhD

9:15 a.m.  Recommendation 6: Implementing Effective Dementia Care
           Kate Possin, PhD

9:27 a.m.  Recommendation 4: Progress and Work Needed to Increase the Dementia Capable Workforce
Heather Snyder, PhD

9:39 a.m. Recommendation 5: Conduct Intervention Studies to Mitigate Reversible Causes of Cognitive Dysfunction
Sharon Inouye, MD, MPH and David Knopman, MD

9:55 a.m. Open Microphone Discussion and Panel – Multiple Etiology Dementias
Alireza Atri, MD, PhD; Patricia Boyle, PhD; Cynthia Carlsson, MD, MS; Sharon Inouye, MD, MPH; David Knopman, MD; Kate Possin, PhD, Heather Snyder, PhD

10:20-10:40 a.m. BREAK

SESSION 2: Health Disparities in AD/ADRD
Chairs: Lisa Barnes, PhD and Hector Gonzalez, PhD

10:40 a.m. Introduction
Lisa Barnes, PhD and Hector Gonzalez, PhD

10:50 a.m. Recommendations 1 and 2: Assessment
Jennifer Manley, PhD

11:06 a.m. Recommendations 3 and 4: Epidemiology and Pathway Analyses Toward Culturally Appropriate Interventions
Rebecca Gottesman, MD, PhD

11:22 a.m. Recommendations 5 and 6: Monitoring Trends
Elizabeth Rose Mayeda, PhD, MPH

11:38 a.m. Recommendation 7: Workforce Development
Luis Medina, PhD

11:54 a.m. Open Microphone Discussion and Panel – Health Disparities in AD/ADRD
Lisa Barnes, PhD; Myriam Fornage, PhD; Hector Gonzalez, PhD; Rebecca Gottesman, MD, PhD; J. Taylor Harden, PhD, RN; Jennifer Manly, PhD; Elizabeth Rose Mayeda, PhD, MPH; Luis Medina, PhD

12:20-1:20 p.m. LUNCH ON YOUR OWN

SESSION 3: Lewy Body Dementias
Chair: Bradley Boeve, MD and Carol Lippa, MD

1:20 p.m. Introduction
1:30 p.m. Clinical Science – Progress and Changes to Recommendations 1-4
   Jennifer Goldman, MD, MS; Kirk Frey, MD; Dennis Dickson, MD

2:05 p.m. Basic Science – Progress and Changes to Recommendations 5-8
   Douglas Galasko, MD, Sonja Scholz, MD, PhD; Mark Cookson, PhD

2:40 p.m. Open Microphone Discussion and Panel – Lewy Body Dementias
   Bradley Boeve, MD; Mark Cookson, PhD; Dennis Dickson, MD; Kirk Frey, MD; Douglas Galasko, MD; Jennifer Goldman, MD, MS; Peter Lansbury Jr, PhD; Carol Lippa, MD; Sonja Scholz, MD, PhD; Angela Taylor, BMus; Daniel Weintraub, MD

3:00-3:20 p.m. BREAK

SESSION 4: Dementia Nomenclature
   Chairs: Ronald Petersen, MD, PhD and Angela Taylor, BMus

3:20 p.m. A Rising National Priority: Recommendations to Form Integrated Workgroups on Nomenclature in Research, Clinical Practice, and Society
   Angela Taylor, BMus

3:25 p.m. Stakeholder Engagement Strategy: The Needs of the Research Community
   Ronald Petersen, MD, PhD

3:40 p.m. Translating the Science into Clinical Practice
   James Leverenz, MD

3:48 p.m. Living with a Dementia Diagnosis: The First-Person Experience
   Cynthia Huling Hummel, BS, MDiv, DMin

3:53 p.m. Insights from a Caregiver
   Mark Herthel, BS

3:58 p.m. Cultural Considerations: Giving Meaning to and Responding to Dementia
   Peggye Dilworth-Anderson, PhD

4:06 p.m. Stigma: Considerations of Ethics and History
   Jason Karlawish, MD and Cara Fiernan Fallon, PhD, MPH

4:14 p.m. Categories and Controversies: Insights from DSM-5
   Dominic Sisti, PhD
4:22 p.m.  Integration of Stakeholder Input and Next Steps  
Sandra Weintraub, PhD, ABCN/ABPP

4:30 p.m.  Open Microphone Discussion and Panel – Dementia Nomenclature  
Peggye Dilworth-Anderson, PhD; Cara Fiernan Fallon, PhD, MPH;  
Mark Herthel, BS; Cynthia Huling Hummel, BS, MDiv, DMin; Jason  
Karlawish, MD; James Leverenz, MD; Ron Petersen, MD, PhD; Dominic  
Sisti, PhD; Angela Taylor; Sandra Weintraub, PhD, ABCN/ABPP

5:00 p.m.  Adjourn Day 1

Friday, March 15, 2019

7:30 a.m.  Registration

SESSION 5: Vascular Contributions to Cognitive Impairment and Dementia  
Chairs: Donna Wilcock, PhD and Jeff Williamson, MD, MHS

8:00 a.m.  Introduction and Overview of Recommendations  
Donna Wilcock, PhD

8:10 a.m.  Basic Science and Mechanisms Recommendations  
Andy Shih, PhD and Roxanna Carare, MD, PhD

8:30 a.m.  Clinical Science Recommendations  
Kristine Yaffe, MD and Eric Smith MD, MPH

8:50 a.m.  Translational Science Recommendations  
Jeff Williamson, MD, MHS

9:10 a.m.  Open Microphone Discussion and Panel – VCID  
Roxanna Carare, MD, PhD; Susan Catalano, PhD; Rebecca Gottesman,  
MD, PhD; Douglas Gould, PhD; Anne Leonard, MPH, RN; Henrieta  
Scholtzova, MD, PhD; Andy Shih, PhD; Eric Smith, MD, MPH; Heather  
Snyder, PhD

9:40-10:00 a.m.  BREAK

SESSION 6: Frontotemporal Lobar Degeneration  
Chairs: Leonard Petrucelli, PhD and Adam Boxer, MD, PhD

10:00 a.m.  Introduction and Changes to Basic Science Recommendations 1-4  
Leonard Petrucelli, PhD
10:05 a.m.  Basic Science: Advances in tau Biology
    Anthony Fitzpatrick, PhD

10:15 a.m.  Basic Science: Advances in FTLD C9ORF72, and GRN Biology
    Jeff Rothstein, MD, PhD and Michael Ward, MD, PhD

10:25 a.m.  Basic Science: Single Cell ‘Omic Analysis for FTLD
    Manolis Kellis, PhD

10:35 a.m.  Open Microphone Discussion and Panel – Basic Science of FTLD
    Patrick Brannelly, MBA; Anthony Fitzpatrick, PhD; Manolis Kellis, PhD;
    Rodney Pearlman, PhD; Leonard Petrucelli, PhD; Jeff Rothstein, MD,
    PhD; Nadine Tatton, PhD; Michael Ward, MD, PhD

10:50 a.m.  Changes Made to Clinical Science Recommendations 5-8
    Adam Boxer, MD, PhD

10:55 a.m.  Clinical Science: Biomarkers
    Henrik Zetterberg, MD, PhD and Jon Rohrer, MD, PhD

11:05 a.m.  Clinical Science: Genetics and Natural History Studies
    Bradley Boeve, MD

11:15 a.m.  Clinical Science: Clinical Trials
    Adam Boxer, MD, PhD

11:25 a.m.  Open Microphone Discussion and Panel – Clinical Science FTLD
    Adam Boxer, MD, PhD; Patrick Brannelly, MBA; Nick Fox, MD; Rodney
    Pearlman, PhD; Jon Rohrer, MD, PhD; Holly Soares, PhD; Nadine
    Tatton, PhD; Henrik Zetterberg, MD

11:40-12:40 p.m.  LUNCH ON YOUR OWN

SESSION 7: Emerging Scientific Topics
    Chairs: Kristen Dams-O’Connor, PhD and Julie Schneider, MD, MS

12:40 p.m.  Introduction to TDP-43 in Common Dementias & Recommendations 1-4
    Julie Schneider, MD, MS

12:45 p.m.  TDP-43 in Common Dementias: Rationale for Clinical Recognition and
    Biomarkers Studies
    Julie Schneider, MD, MS

12:50 p.m.  Rationale for Studying Risk Factors, Genetic Drivers and Pathologic
    Phenotypes of TDP-43 in Common Dementias
Pete Nelson, MD, PhD

1:00 p.m. Rationale for Basic Science and Animal Model Studies Specifically Targeted Toward TDP-43 in Common Dementias
Aaron Gitler, PhD

1:10 p.m. Open Microphone Discussion & Panel – TDP-43 in Common Dementias
Aaron Gitler, PhD; Pete Nelson, MD, PhD; Julie Schneider, MD, MS

1:30 p.m. Introduction to TBI and AD/ADRD Risk
Kristen Dams-O’Connor, PhD

1:40 p.m. Summary of NIH/VA-ORD Workshop: TBI as a Risk Factor for AD/ADRD among Veterans
Kristen Dams-O’Connor, PhD

1:45 p.m. Recommendations 5-8 for the Study of TBI and AD/ADRD Risk
Kristen Dams-O’Connor, PhD

1:50 p.m. Open Microphone Discussion and Panel – TBI and AD/ADRD Risk
Kristen Dams-O’Connor, PhD; Mary Jo Pugh, PhD, RN; Douglas H. Smith, MD; Henrik Zetterberg, MD, PhD

2:20-2:30 p.m. BREAK

WRAP-UP

2:30 p.m. Scientific Chair’s Highlights and Cross-Cutting Themes
Julie Schneider, MD, MS, Scientific Chair

2:55 p.m. Further Public Input and Open Microphone Discussion
Lisa Barnes, PhD; Bradley Boeve, MD; Adam Boxer, MD, PhD; Kristen Dams-O’Connor, PhD; Hector Gonzalez, PhD; David Knopman, MD; Carol Lippa, MD; Ronald Petersen, MD, PhD; Leonard Petrucelli, PhD; Kate Possin, PhD; Julie Schneider, MD, MS; Angela Taylor, BMus; Donna Wilcock, PhD; Jeff Williamson, MD, MHS

3:20 p.m. Conclusion of ADRD Summit 2019
Biographies

Scientific Chair, ADRD Summit 2019

**Julie A. Schneider, MD, MS** is the Deborah R. And Edgar D. Jannotta Presidential Professor of Pathology (Neuropathology) and Neurological Sciences, and Associate Director at the Rush Alzheimer’s Disease Center, at Rush University Medical Center. She completed her Neurology residency at the University of Chicago and Neuropathology fellowship at Emory University in Atlanta and is board certified in both specialties. Dr. Schneider is also certified in Geriatric Neurology, and has a Master’s Degree in Clinical Research with a focus in Epidemiology. She is the Neuropathology Core Leader of the Rush Alzheimer’s Disease Center and the senior neuropathologist for multiple studies including the Religious Orders Study, Rush Memory and Aging Project, and Rush Minority Aging Research Study, Rush Latino Core, and NCRAD (National Cell Repository for Alzheimer’s disease). Dr. Schneider has provided peer review for over 25 journals; has been invited to multiple journal editorial boards; and has provided numerous grant peer reviews for the National Institutes of Health, Alzheimer’s Association, and other agencies. She has served on numerous scientific and external national and international advisory boards for academia and industry; and has presented findings from her research both nationally and internationally. Dr. Schneider has extensive experience with clinical-pathologic epidemiologic studies of aging and dementia and has over 300 peer-reviewed publications and 4 book chapters. She also has extensive experience collaborating with researchers, participating in multicenter grants and initiatives, and partnerships with industry to advance science. The foundation of Dr. Schneider’s research is the exploration of pathologic factors in the clinical expression of cognitive decline in aging, with a focus on vascular, TDP-43, hippocampal sclerosis and mixed pathologies in Alzheimer’s and related dementias. Her current research leverages neuropathology to advance biomarker development.

Chair of the Advisory Council on Alzheimer’s Research, Care, and Services

**Laura N. Gitlin, PhD, FGSA, FAAN**, an applied research sociologist, is the dean of the College of Nursing and Health Professions at Drexel University. Dr. Gitlin is nationally and internationally recognized for her research on developing, evaluating and implementing novel home and community-based interventions that improve quality of life of persons with dementia and their family caregivers, enhance daily function of older adults with disability and address mental health disparities. She is a well-funded researcher, having received continuous research and training grants from federal agencies and private foundations for over 35 years. In all of her research, she applies a social ecological perspective and person—family-directed approach to examine, intervene and support individuals. Her efforts involve collaborating with community organizations, health and human service professionals and other stakeholders to maximize the relevance and impact of such interventions. She is also involved in translating, disseminating and implementing proven programs for delivery in diverse practice settings globally and in the United States. She is the author of close to 300 scientific publications including authoring or co-authoring seven books, the most recent published in 2016 on behavioral intervention...
research, and 2018 co-authored book, Better Living with Dementia: Implications for Individuals, Families, Communities, and Society. Finally, she is an appointee to the Health and Human Service’s Advisory Council for the National Alzheimer’s Project Act and its current chair. She recently co-chaired the first national effort to develop and implement the first National Research Summit on Care and Services for Persons Living with Dementia and their Caregivers. She is also a recent appointee to the medical advisory board, Alzheimer’s Association and member of the international Lancet Commission on dementia care.

Session Charis

**Lisa L. Barnes, PhD** is the Alla V. and Solomon Jesmer Professor of Gerontology and Geriatric Medicine in the department of Neurological Sciences at Rush University Medical Center, and a cognitive neuropsychologist in the Rush Alzheimer’s Disease Center. Dr. Barnes received her PhD from the University of Michigan and completed an NIH-sponsored post-doctoral training program in cognitive neuroscience at the University of California, Davis, before joining the faculty at Rush Medical College in 1999. Her research focus is on racial disparities in chronic diseases of aging. She is the Principal Investigator of three community-based cohort studies of older African Americans and has published extensively on aging-related conditions in older African Americans, including cognitive decline, Alzheimer’s disease, and the intersection of HIV and aging. She is an advocate for recruitment of older minorities into clinical research and does extensive education in the community on awareness of Alzheimer’s and other dementias. She has received numerous awards and fellowships and serves on several national committees.

**Bradley F. Boeve, MD** is a neurologist with subspecialty training in behavioral/cognitive neurology and sleep medicine. Over the past 20+ years he has focused work on the clinical, sleep, neuropsychological, genetic, neuroimaging, and neuropathologic aspects of the neurodegenerative disorders which manifest as cognitive impairment and/or parkinsonism. These disorders include mild cognitive impairment and/or mild parkinsonian signs, dementia with Lewy bodies/Parkinson's disease with dementia, the frontotemporal lobar degeneration (FTLD)-spectrum disorders, and the rapidly progressive dementias such as Creutzfeldt-Jakob disease and the autoimmune/inflammatory encephalopathies. The prodromal features of evolving Lewy body disease (namely REM sleep behavior disorder) as well as overt Lewy body dementia, and the presymptomatic and early symptomatic phases of the genetically-mediated FTLD-spectrum disorders, are his particular interests; he is involved in several NIH-funded protocols focusing on these disorders. He has worked with many colleagues at Mayo Clinic at other academic institutions in the US and abroad to advance knowledge in the Alzheimer’s disease-related dementias.

**Adam L. Boxer, MD, PhD** is Endowed Professor in Memory and Aging in the Department of Neurology at the University of California, San Francisco (UCSF). He directs UCSF’s Neurosciences Clinical Research Unit and the Alzheimer’s Disease and Frontotemporal Degeneration (FTD) Clinical Trials Program at the UCSF Memory and Aging Center. Dr. Boxer’s research is focused on developing new treatments and biomarkers for neurodegenerative diseases, particularly those involving tau and TDP-43. He is the Principal Investigator of the Advancing Research and Treatment for FTLD (ARTFL) Rare Disease Clinical Research Consortium, a collaborative project funded by the National Institutes of Health to create an 18 center North American research network to support the development of new therapies for FTLD. He
also leads the Four Repeat Tauopathy Neuroimaging Initiative (4RTNI), a multicenter, longitudinal tau PET and biomarker study focused on PSP and CBD. He has been the PI for a variety of multicenter, randomized, placebo controlled clinical trials in FTLD spectrum disorders, including memantine for FTLD, davunetide for PSP, TPI-287 for primary and secondary tauopathies, and salsalate for PSP. He co-chairs the FTLD Treatment Study Group (FTSG) and the PSP Research Roundtable, an academic-industry collaborative group working to speed the development of new therapies for FTLD, CBD and PSP.

**Kristen Dams-O’Connor, PhD** is Director of the Brain Injury Research Center of Mount Sinai and Associate Professor in the Departments of Rehabilitation Medicine and Neurology at Icahn School of Medicine at Mount Sinai in New York, NY. She completed a Bachelor’s Degree in Behavioral Neuroscience at Colgate University, a PhD at the University at Albany, doctoral training at the Rusk Institute of Rehabilitation Medicine at New York University Medical Center and then completed a postdoctoral fellowship in Clinical Neuropsychology at Mount Sinai Medical Center. Her clinical expertise is in neuropsychological assessment and intervention for individuals with neurological diseases. Dr. Dams-O’Connor’s research is focused on applying modern psychometric and statistical techniques to measure individual differences in trajectories of change over time among survivors of TBI and identifying mechanisms, risk and protective factors for post-traumatic neurodegeneration. She leads the Late Effects of TBI (LETBI) Project, a TBI brain donor program focused on characterizing the clinical phenotype and postmortem pathological signatures of post-traumatic dementia and their associations with Alzheimer’s disease and related dementias. She is also Project Director of the New York Traumatic Brain Injury Model System of care, one of 16 centers of excellence for TBI research in the United States. Her research is currently supported by federal grants from the National Institutes of Health, National Institute for Disability Independent Living and Rehabilitation Research, Department of Defense, Centers for Disease Control, and Patient Reported Outcomes Research Institute. She has published over 70 peer-reviewed manuscripts and chapters on traumatic brain injury treatments and outcomes, and has presented her research internationally.

**Cara Kiernan Fallon, PhD, MPH** is a postdoctoral fellow in biomedical ethics at the University of Pennsylvania Perelman School of Medicine in the Department of Medical Ethics and Health Policy and a scholar at the Penn Memory Center. Dr. Fallon is a historian of medicine, public health, and medical ethics whose research has analyzed the rise of the healthy aging practices in the twentieth century alongside evolving relationships between medicine, public health, the commercial marketplace, and aging Americans. Her current research emphasizes moral and ethical dimensions of aging, caregiving, and chronic disease. She completed her PhD in the History of Science at Harvard University and her MPH at the Yale School of Public Health.

**Hector M. González, PhD** is an Associate Professor in the Department of Neurosciences and Shiley-Marcos Alzheimer’s Disease Research Center in the School of Medicine at the University of California, San Diego. He is a licensed clinical neuropsychologist with clinical research training and experiences in Alzheimer’s disease and related dementias. Dr. González was a clinical research fellow and later co-investigator of the Sacramento Area Latino Study on Aging (SALSA), which is a landmark dementia study among Mexican-origin Latinos. He served as Principle Investigator of the Hispanic Community Health Study/Study of Latinos (HCHS/SOL), Neurocognitive Reading Center. Dr. González is PI of the Study of Latinos-Investigation of neurocognitive aging (SOL-INCA), which is the largest study of Latino neurocognitive health and aging to-date examining sociocultural, cardiometabolic and genomic risks of
Mild Cognitive Impairment (MCI) and ADRD among diverse middle-aged and older Latinos. Dr. González serves on numerous state and national advisory and editorial boards. His research efforts are primarily focused on population-based cardiovascular and neuroepidemiologic studies of midlife markers of brain aging, neurocognitive decline, and ethical/racial inequalities in Alzheimer’s disease and related dementias among diverse Latinos.

David Knopman, MD is a behavioral neurologist at the Mayo Clinic involved in research in late-life cognitive disorders. Dr. Knopman’s specific interests are in the very early stages of Alzheimer’s disease, in cognitive impairment due to stroke (cerebrovascular disease) and in cognitive impairment due to frontotemporal degeneration. He is involved in epidemiology, clinical trials and diagnostic studies of these disorders. He is the immediate past chair of the Medical Scientific Advisory Council of the Alzheimer’s Association and currently a member of its Strategic Advisory Group.

Ronald C. Petersen, MD, PhD is Professor of Neurology, Mayo Clinic College of Medicine, the Cora Kanow Professor in Alzheimer’s Disease Research, and a Mayo Clinic Distinguished Investigator. He is Director of the Mayo Alzheimer’s Disease Research Center and is on the World Dementia Council. He has served as the chair of the Advisory Council on Research, Care and Services for the National Alzheimer’s Project Act. Dr. Petersen is a recipient of the 2004 MetLife Foundation Award for Medical Research in Alzheimer’s Disease, the 2005 Potamkin Prize for Research in Pick’s, Alzheimer’s and Related Disorders as well as the Zaven Khachaturian Award and Henry Wisniewski Award for Lifetime Achievement from the Alzheimer’s Association.

Carol Lippa, MD is an academic neurologist with an international reputation in the neurobiology of aging, Alzheimer’s disease and the related disorders, particularly dementia with Lewy bodies (DLB). She has 30 years of experience in clinical assessment, clinical trials, tissue banking, and clinicopathologic correlation studies for AD, DLB and the related dementias. She went to medical school and completed Neurology and Neuropathology residencies at the University of Massachusetts Medical School, and then completed a clinical and research fellowship in the Neurobiology of Aging. Early in her academic career she published widely on clinicopathologic aspects of DLB, supported by her NIH R29 grant entitled “dementia with parkinsonian: what are we diagnosing.” Her involvement with DLB extends as far back as the first (1995) international DLB “consensus” meeting in Newcastle upon Tyne, England. Dr. Lippa designed and developed Cognitive Disorders Program from the ground up, for 21 years, at Drexel University College of Medicine, and is currently Director of the Farber Institute for Neurosciences’ Cognitive Disorders and Comprehensive Alzheimer’s Center at Thomas Jefferson University (FIN/TJU) which she also developed. She has been a member in many of the multidisciplinary DLB meetings focusing on establishing and refining diagnostic criteria. Dr. Lippa both organized the session and wrote the NIH grant for the “PDD and DLB at a crossroads” satellite session (World Parkinson Congress: PDD, 2006, Washington, DC) and gave the opening statement as well as an overview of biological issues. She was lead author on the manuscript [Neurology 68:812-819, 2007] that resulted from that meeting. Dr. Lippa has over 30 peer reviewed publications relating to LBD, many of which she is first author. She is longstanding member of the LBDA Scientific Advisory group, and is PI at Thomas Jefferson Universities Research Center of Excellence (RCOE) for LBD.

Leonard Petrucelli, PhD is a consultant and chair of the Department of Neuroscience at Mayo Clinic in Florida. He holds the academic rank of professor of neuroscience and has full faculty privileges in molecular neuroscience at Mayo Graduate School. He is recognized as the Ralph B. and Ruth K. Abrams
Professor. Dr. Petrucelli earned his Bachelor of Science degree at Barry University, Miami, and his Ph.D. degree in molecular and cellular biochemistry at Loyola University and Stritch School of Medicine, Chicago. He came to Mayo Clinic's Florida campus as a research fellow in 2000 and joined the neurosciences research staff two years later. Dr. Petrucelli and his research team are at the forefront of their field, researching the cellular mechanisms that cause neurodegeneration in Alzheimer's disease, amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, and frontotemporal dementia (FTD). By combining expertise in drug discovery, cell biology and induced pluripotent stem cell (iPSC) modeling, his lab aims to develop therapies for the treatment of diseases characterized by abnormal protein aggregation. Dr. Petrucelli's team recently discovered a new therapeutic target and biomarker with the aim of improving the diagnosis and prognosis for patients suffering from FTD and ALS. His team’s research has been published in top tier journals including Science, Nature Medicine, Nature Neuroscience, Neuron, Journal of Clinical Investigation and Annals of Neurology. Dr. Petrucelli is principal investigator for several grants funded by the National Institutes of Health (NIH) including R35 and is director of two funded NIH programs focused on c9orf72 and tau. He serves on the Scientific Advisory Board of Science Translational Medicine. He is also the Chief Scientific Advisor to Target ALS Foundation. Lastly, he was recently appointed as vice-chair to the Florida Alzheimer’s Disease Research Grant Advisory Board.

Kate Possin, PhD earned her BA from Tufts University and PhD degree in clinical psychology from the University of California, San Diego. During her training at UCSD, she studied the cognitive changes associated with Parkinson’s disease. She completed her internship and fellowship at the University of California – San Francisco with Bruce Miller and Joel Kramer, where she is currently an Associate Professor in Residence. Dr. Possin’s research program is focused on improving the detection, diagnosis, and care for people with neurodegenerative disease. She has long-standing interests in understanding the cognitive impairments and their neural bases in neurodegenerative diseases including Alzheimer’s disease, Lewy body disease, Huntington’s disease, and frontotemporal lobar degeneration. She is the Project Lead of TabCAT, a software for tablet-based cognitive testing frequently used in research studies and more recently clinical services. The Brain Health Assessment is a 10-minute assessment on TabCAT designed for the detection of cognitive impairment in everyday clinical settings. She also the Principal Investigator of the Care Ecosystem, a telephone-based supportive care program for persons with dementia and their caregivers. Dr. Possin is a faculty member at the Global Brain Health Institute.

Angela Taylor, BMus is the Senior Director of Research and Advocacy for the Lewy Body Dementia Association (LBDA), where she contributes to the strategy and leadership of all research, advocacy and educational activities of the organization. Mrs. Taylor plays a central role in LBDA’s Research Centers of Excellence, patient engagement in research, and educational programming for both lay and professional audiences. Bringing a personal connection to LBD as a family caregiver for her father and 15 years contributing to the mission of LBDA, she is a regularly-invited speaker at scientific and educational conferences on the impact of LBD on those diagnosed and their family caregivers. An internationally-recognized LBD advocate, she serves on the U.S. Advisory Council on Alzheimer’s Research, Care and Services.

Donna M. Wilcock, PhD is the Sweeney-Nelms Endowed Professor in Alzheimer’s Disease Research and Professor of Physiology at the Sanders-Brown Center on Aging, University of Kentucky in Lexington, KY. Dr. Wilcock’s research is focused on vascular contributions to cognitive impairment and dementia.
(VCID) and spans animal models and human-based studies. She has mechanistic studies focusing on the neurovascular astrocyte, its degeneration in VCID, and its role in vascular inflammation. Dr. Wilcock is the PI of the University of Kentucky site for MarkVCID, a biomarker consortium funded by NINDS and NIA. She also leads the University of Kentucky-Alzheimer’s Disease Center Biomarker Core. Her research is currently funded by the NINDS and NIA.

**Jeff D. Williamson, MD, MHS** is Professor of Internal Medicine and Epidemiology. He is also Chief, Section on Gerontology and Geriatric Medicine at Wake Forest University School of Medicine. He is an internationally known geriatrician and clinical trialist. Dr. Williamson serves as Director of the Center for Healthcare Innovation, Co-Leader, Alzheimer’s Disease Research Center Clinical Core, Clinical Core Principal Investigator for the Wake Forest Claude Pepper Older Americans Independence Center and the Wake Forest John A. Hartford Center of Excellence. Dr. Williamson received his M.D. from the Medical College of Georgia, a Master's degree in Epidemiology from the Johns Hopkins University School of Hygiene and Public Health and completed his fellowship in Geriatric Medicine at Johns Hopkins. Dr. Williamson’s primary research interests are in understanding relationships between chronic diseases such as hypertension and diabetes and maintaining brain health and physical function in aging adults, the prevention of aging-related loss of independence, and in developing research methods for including elderly persons in clinical trials. His most recent work is in developing and testing approaches to improving care coordination for vulnerable elderly patients as they traverse the health care system. Dr. Williamson is currently serving on the leadership team for 3 nationwide research studies funded by the National Institutes of Health. Altogether, his NIH research studies have involved more than 30,000 adults over age 65 and 15,000 persons over age 75

**Panelists**

**Alireza Atri, MD, PhD** is a cognitive neurologist, neuroscientist, clinical researcher and educator in the fields of Alzheimer’s disease (AD) and Related Dementias (ADRD). He is the Director of the Banner Sun Health Research Institute, Sun City, AZ, and also serves on the neurology faculty at Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA. He specializes in the care of individuals with cognitive disorders and dementia, particularly individuals with early-onset AD/ADRD. Dr. Atri holds degrees from U.C.L.A. (Ph.D Biomathematics), U.C.S.F. (M.D.) and Harvard Medical School (M.M.Sc.). He completed post-graduate training and clinical and research fellowships at Harvard Medical School, Boston University and MIT, and served on the faculty of Massachusetts General Hospital for 15 years. His research focuses on early detection, risk reduction, experimental therapeutics and best care practices in AD/ADRD and has aimed to: 1) Quantify progression of symptoms in AD/ADRD and the effects of interventions on slowing clinical decline; 2) Detect the fingerprints of AD and the effects of interventions by combining psychometrics and neuroimaging and psychophysiological biomarkers; 3) Assess cognitive reserve and effects of lifestyle on retarding decline and reducing dementia risk; 4) Design measurement tools and statistical methods for AD/ADRD clinical trials; 5) Establish evidence-based guidelines to support best practices in evaluation and care of AD/ADRD. Dr. Atri serves as co-chair of the Alzheimer’s Association U.S. national best clinical practices (AADx-CPG) workgroup on evaluation of cognitive behavioral syndromes and AD/ADRD, and as the vice chair of the Alzheimer’s Disease International (ADI) Medical Scientific Advisory Panel. He has delivered over 250 invited continuing
education programs/grand rounds; presented 200 conference papers; and authored more than 70 papers and book chapters. He is co-author and editor of Dementia: Comprehensive Principles and Practices, Oxford University Press, 2014.

*Patricia Boyle, PhD* is Professor of Behavioral Sciences, and a neuropsychologist at the Rush Alzheimer’s Disease Center at Rush University Medical Center in Chicago, IL. Dr. Boyle received her PhD from the University of Massachusetts at Amherst and completed her postdoctoral fellowship at Brown University in Providence, RI. Her primary research interest is the prevention of cognitive and functional decline in old age. Her studies examine risk factors for and the neurobiologic basis of age-related changes in cognition, financial and health decision making, and well-being. Dr. Boyle’s research has been continuously funded by the National Institute on Aging for nearly 2 decades and she has published extensively, with more than 180 peer-reviewed publications. Dr. Boyle also leads Research Education at the Rush Alzheimer’s Disease Center and serves on national advisory committees on aging and Alzheimer’s disease.

*Patrick Brannelly, MBA* is the Program Director of the Rainwater Foundation’s Tau Consortium, whose mission is to accelerate the development of new treatments for Alzheimer’s disease, frontotemporal dementia, and other tauopathies. In the decade prior to joining the Tau Consortium, Mr. Brannelly was the co-founder and CEO of NeoCORTA and the Director of Group Programs at Posit Science, both brain health technology ventures. Earlier in his career, he served in the US and Europe as a management consultant in the pharmaceutical, energy, and technology sectors. He is a former Assistant Professor in entrepreneurship and strategy at California State University, Fresno. He currently serves as a Board member of the FTD Disorders Registry, a Steering Committee member of the PSP Research Roundtable, and the Co-Managing Director of the PSP Genetics Consortium. He is a former Board member of the Alzheimer’s Association, National Capital Chapter. Mr. Brannelly holds a BA in Psychology from Harvard College and an MBA with Distinction from Harvard Business School.

*Roxana Carare, MD, PhD* is qualified in Medicine in Bucharest in 1994. During her basic clinical training, she became fascinated by anatomy and completed her PhD in experimental neuropathology in 2006, in the University of Southampton, UK. She was appointed lecturer in 2001, associate professor in 2014 and professor of clinical neuroanatomy in 2016. The main international recognition for Roxana Carare has come from the interdisciplinary research she leads, investigating the cause of Alzheimer’s disease and suggesting therapeutic strategies. Roxana is a member of the MRC Dementia Platform UK Vascular Experimental Medicine committee and the UK government advisory committee for the effects of pollution on the brain. The Carare team has won prestigious awards, including a Dementia Research Leader award from Alzheimer’s Society UK. Roxana has enjoyed teaching anatomy for 20 years, with a passion for neuroanatomy. Roxana chairs the committee for equality, diversity, intersectionality and inclusivity in the Faculty of Medicine, University of Southampton and is Co-Chair for The International Alliance of Women Alzheimer’s Researchers in Alzheimer’s Association

*Cynthia Carlsson, MD, MS* is researching the effects of vascular risk factors and their treatments on cognition and biomarkers for Alzheimer’s disease in persons at risk for dementia. Vascular risk factors in midlife, such as high cholesterol and elevated blood pressure, have been associated with an increased risk of developing Alzheimer’s disease decades later. It is unknown, however, whether treating vascular risk factors will reduce the risk of dementia. Through partnering with research participants and colleagues in geriatrics, neuropsychology, cardiovascular medicine, neuroradiology, medical physics, and
clinical chemistry. Dr. Carlsson's work has been supported by the National Institute on Aging (NIA), the American Federation for Aging Research (AFAR), the John A. Hartford Foundation, Atlantic Philanthropies, the Starr Foundation, the state of Wisconsin and the University of Wisconsin Department of Medicine and the General Clinical Research Center. Through their work, Dr. Carlsson and her colleagues hope to identify preclinical markers of Alzheimer’s disease risk as well as effective treatment strategies to delay the onset of dementia in persons at risk for the disease.

**Susan Catalano, PhD** is a founder of Cognition Therapeutics, Inc. where she serves as Chief Science Officer, with responsibility for the company’s scientific strategy and R&D pipeline and operations. Dr. Catalano guided the discovery and development of the company’s first Alzheimer’s candidate drug CT1812 (ElaytaTM), currently in clinical trials in AD patients. Prior to founding Cognition Therapeutics, Dr. Catalano was Director of Discovery Biology for Acumen Pharmaceuticals, Inc., leading the team that discovered some of the industry’s first drug candidates targeting Aβ oligomers. Prior to this, at Rigel Pharmaceuticals she led the team that pioneered the use of phenotypic screening to discover the Aurora kinase inhibitor R763, licensed to Serono for use against solid tumors. While a scientist at Roche Palo Alto, she led the Neurophysiology and Neuroimaging groups along with an exploratory program in psychiatric disorders. Dr. Catalano received her B.A. from Barnard College and Ph.D. from U.C. Irvine, with postdoctoral training at U.C. Berkeley and Caltech. She also holds an adjunct appointment at the University of Pittsburgh School of Medicine. She is a 2015 EY Entrepreneurial Winning Women awardee. In 2016, CogRx received the Luis Villalobos Award for most innovative company from the Angel Capital Association.

**Mark R. Cookson, PhD** is a cell biologist whose current research interests include the effects of mutations in the genes associated with neurodegeneration at the cellular and molecular level. His laboratory efforts are directed at finding the underlying pathways that lead to Parkinson's disease and related disorders. Dr. Cookson received both his B.Sc. and Ph.D. degrees from the University of Salford, UK in 1991 and 1995, respectively. His postdoctoral studies included time spent at the Medical Research Council laboratories and at the University of Newcastle, Newcastle, UK. He joined the Mayo Clinic, Jacksonville, Florida, as an Assistant Professor in 2000 and moved to the NIA in February 2002. Within the Laboratory of Neurogenetics, Dr. Cookson's group works on the effects of mutations associated with Parkinson's disease on protein function.

**Dennis W. Dickson, MD** concentrates his research on the neuropathologic characterization of brains from prospective and longitudinal research cohorts, such as the Mayo Clinic Alzheimer's Disease Center and the Einstein Aging Study. His research on non-Alzheimer’s degenerative diseases includes frontotemporal degenerations with or without motor neuron disease, Lewy body dementia and atypical Parkinsonian disorders such as progressive supranuclear palsy and multiple system atrophy. He is director of the brain bank for neurodegenerative disorders at Mayo Clinic. These studies aim to understand the molecular pathology of neurodegenerative disorders that will lead to improved diagnostic accuracy and future therapies. Dr. Dickson’s professional highlights include the 2011 Potamkin Prize from the American Academy of Neurology and the 2017 MetLife Foundation Award. He is past president of the American Association of Neuropathologists and was recognized for Meritorious Service to Neuropathology in 2016.

**Peggye Dilworth-Anderson, PhD** is professor of Health Policy & Management at the Gillings School of Global Public Health, University of North Carolina- Chapel Hill. Her research focus is on health
disparities and Alzheimer’s disease with an emphasis on building knowledge for the scientific and lay community to inform conducting culturally relevant research and disseminating information about Alzheimer’s disease and related disorders in medically underserved diverse populations. She is the 2010 recipient of the Ronald & Nancy Reagan Alzheimer’s Research Award for her research contributions on Alzheimer’s disease in medically underserved populations. Dr. Dilworth-Anderson has served in numerous leadership roles that address health and aging issues, including: Board of Directors of the National Alzheimer’s Association (2001-2009), National Alzheimer’s Association Medical and Scientific Council (2006-2011), National Research Advisory Council of the Institute on Aging/NIH (2007-2011), President, Gerontological Society of America (2010), Forum on Aging, Disability & Independence-National Academies of Sciences, Engineering, and Medicine (2012 – 2014), Global Council on Brain Health (2015-present), and Board of Directors of the Alzheimer’s Association Eastern North Carolina Chapter (2015- present). Dr. Dilworth-Anderson has taught courses in aging and translational health disparities. In addition to teaching, she has dedicated many years to mentoring graduate and medical students, fellows, and junior and mid-career faculty interested in the field of aging. In recognition of her mentoring, she received the Minority Task Force Mentor Award in 2006 from the Gerontological Society of America and the UNC Faculty- to- Faculty Mentoring Award in 2012 from the Carolina Women’s Leadership Council.

Anthony W.P. Fitzpatrick, PhD is an Assistant Professor of Biochemistry and Molecular Biophysics at the Zuckerman Institute, Columbia University, New York, USA. Previously, he was a Marie Curie International Outgoing Fellow at the Laboratory of Molecular Biology, University of Cambridge (2015-2017) and the California Institute of Technology (2012-2014). He has a biophysics background (Ph.D. with Professor Sir Christopher M. Dobson, University of Cambridge) and undertook postdoctoral training with Professors Helen Saibil in London, Robert G. Griffin at the Massachusetts Institute of Technology, Ahmed H. Zewail (Nobel Laureate) at the California Institute of Technology and Sjors Scheres and Michel Goedert at the Laboratory of Molecular Biology, Cambridge. The research focus of the Fitzpatrick lab is to determine the structure and behavior of patient-derived amyloid fibrils and, more generally, understanding the role of protein aggregation in vivo by identifying the cellular changes that occur in response to the formation, clearance and spread of fibrillar inclusions. The methods employed by his lab are largely experimental and include cryo-electron microscopy, mass spectrometry, transcriptomics, microfluidics, and optical super-resolution microscopy.

Myriam Fornage, PhD is Professor of Molecular Medicine and Human Genetics and the Laurence and Johanna Favrot Distinguished Professor at the University of Texas Health Science Center at Houston, Texas. She is a molecular epidemiologist with an active research program on the genomics of brain vascular disease and brain aging in well-characterized and diverse populations from young adulthood to old age. She is an investigator of several large national and international consortia, including the Cohorts of Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium, the NHLBI Trans-Omics for Precision Medicine (TOPMed) Program, and the NIA Alzheimer Disease Sequencing Project (ADSP). She has served on several NIH expert advisory panels, including as a member of the Genetics of Health and Disease (GHD) study section. She is a member of the Leadership Committee of the American Heart Association Council on Genomic and Precision Medicine.

Nick Fox, MD is Professor of Clinical Neurology at UCL’s Institute of Neurology. He directs the Dementia Research Centre and is the Associate Director for the UK DRI at UCL. He is also a consultant
neurologist at the National Hospital for Neurology and Neurosurgery, Queen Square, London. His first degree was in Physics and Physiology from Cambridge. He graduated in Medicine from the University of London and subsequently specialized in cognitive neurology. He has clinical and research interests in neurodegenerative dementia which range from biomarker and imaging methods to improve diagnosis and accelerate drug discovery through to supporting patients and families with young onset, inherited and atypical dementias. He has published over 400 peer-reviewed papers. He helped establish the first UK support groups for atypical and inherited dementias. He was a member of the Prime Minister’s Dementia Research Champions Group 2013-15. He chairs UCL’s Dementia Strategy Board and co-chairs the Leonard Wolfson Experimental Neurology Centre at Queen Square. He is a member of the UK’s Alzheimer’s Society’s Research Strategy Council. He is a Fellow of the Academy of Medical Sciences. He was awarded the 2017 Weston Brain Institute International Outstanding Achievement Award.

**Kirk Frey, MD, PhD** is interested in general aspects of synaptic neurochemical markers and in neuroimaging. Our goals are ultimately to provide direct imaging measures of the effects of diseases and therapies in the human brain, thus, advancing our understanding of neurologic and psychiatric illness and permitting the development of better therapies. He is actively pursuing the development and characterization of markers specific to each of two cell types involved in disorders of memory and cognition (cholinergic neurons) or in psychosis and movement disorders (dopaminergic neurons). He is developing and applying new, non-invasive methods for imaging of receptors and other markers in the human brain based on positron emission tomography (PET). The possibility of drug-induced changes in receptor numbers may be investigated in the human brain at therapeutically relevant drug doses. This latter information may help identify mechanisms underlying drug intolerance.

**Douglas Galasko, MB, BCh** completed medical training in South Africa, Neurology Residency at Johns Hopkins Medical School and Fellowship training in dementia/geriatric Neurology at UCSD. He is a Professor in the Department of Neurosciences at UCSD and a Staff Physician at the VA Medical Center and has leadership roles in the NIA-funded Alzheimer’s Disease Research Center and the Alzheimer’s Disease Cooperative Study. His research interests include risk factors, diagnostic criteria and biomarkers for neurodegenerative disorders, as well as using biomarkers to aid in novel therapeutic development. He has authored over 350 journal articles. He has participated in developing diagnostic criteria for AD, DLB and FTD, as well as guidelines for appropriate use of CSF biomarkers for AD. He serves as advisor to the Michael J Fox Foundation, the LBDA, as grant reviewer for NIH and a number of Foundations and organizations, and as Editor of Alzheimer’s Research & Therapy.

**Aaron D. Gitler, PhD** is Professor of Genetics at Stanford University. He received his B.S. degree from Penn State University and did his PhD studies on cardiovascular development in the laboratory of Dr. Jonathan Epstein at the University of Pennsylvania. Then he performed his postdoctoral training with Dr. Susan Lindquist at the Whitehead Institute for Biomedical Research and MIT. In 2007, he established his laboratory at the University of Pennsylvania and moved to Stanford in 2012. His laboratory has been using a combination of yeast and human genetics approaches to investigate pathogenic mechanisms of ALS and FTD. His research has been recognized by several awards. These include being named a Pew Scholar in the Biomedical Sciences and a Rita Allen Scholar. He was a recipient of the NIH Director’s New Innovator Award and the NINDS Research Program Award.

**Jennifer G. Goldman, MD, MS, FAAN, FANA** is a Movement Disorders neurologist with board certification in Behavioral Neurology and Neuropsychiatry. Dr. Goldman is the Section Chief for
Parkinson’s Disease and Movement Disorders at the Shirley Ryan Abilitylab (formerly Rehabilitation Institute of Chicago) and Professor of Physical Medicine and Rehabilitation and Neurology at Northwestern University Feinberg School of Medicine. Previously, Dr. Goldman was Professor of Neurological Sciences and director of the Lewy Body Dementia Association (LBDA) Research Center of Excellence at Rush University. Dr. Goldman graduated from Princeton University and completed her MD at Northwestern University Medical School, Neurology residency at Washington University in St. Louis, and Movement Disorder fellowship and Master of Science in Clinical Research at Rush University. Her work is well known regarding Lewy body disorders (LBDs), particularly Parkinson’s disease (PD) mild cognitive impairment, PD dementia, and Dementia with Lewy Bodies, and she has served on the Task Forces that developed diagnostic criteria for these disorders. As a clinician, Dr. Goldman treats patients with Lewy body disorders and other conditions, using a holistic, team-based approach for the patient and care partner. Her research investigates mechanisms of cognitive and behavioral issues in LBDs using neuroimaging and biomarkers and also interventions to prevent or treat these complications. Her work has been funded by NIH, Michael J. Fox Foundation, Parkinson’s Foundation, among others. Dr. Goldman chairs the LBDA Scientific Advisory Committee, the International Parkinson’s Disease and Movement Disorder Society Pan-American Education Committee, and the American Academy of Neurology Movement Disorder section.

Rebecca Gottesman, MD PhD is a Professor of Neurology in the Cerebrovascular Division at the Johns Hopkins University School of Medicine, where she is also a Core Faculty member of the Welch Center for Prevention, Epidemiology, and Clinical Research and holds a joint appointment in Epidemiology at the Johns Hopkins Bloomberg School of Public Health. She completed her undergraduate and medical training at Columbia University, then did neurology residency and a vascular neurology fellowship at the Johns Hopkins Hospital and completed a PhD in Clinical Investigation at the Johns Hopkins Bloomberg School of Public Health. Dr. Gottesman primarily conducts research as part of the Atherosclerosis Risk in Communities (ARIC) study. Her research, funded primarily by the NIH, focuses on the vascular contribution to cognitive impairment and dementia, including Alzheimer’s Disease (AD). She recently received the Outstanding Stroke Research Mentor award at the 2019 International Stroke Conference. Dr. Gottesman has served as a member of both American Heart Association (AHA) and NIH study sections. She is also Associate Editor for Epidemiology for the journal Neurology and is the Director of Clinical Research for Neurology on the Johns Hopkins Bayview Medical Center campus.

Douglas B. Gould, PhD is a Professor of Ophthalmology and Anatomy at UCSF School of Medicine. He holds the Denise B. Evans Endowed Chair in Ophthalmology and is the Director of Research for the Department of Ophthalmology. Doug earned both a BSc in Biological Sciences with Specialization in Genetics in 2006 and a PhD in Medical Genetics in 2001 from the University of Alberta. The same year, he moved to The Jackson Laboratory for postdoctoral training where he discovered the first pathogenic mutations in type IV collagen alpha 1 (COL4A1) which encodes a major component of all basement membranes. His early work on the role of COL4A1 mutations in porencephaly earned him a fellowship from the Canadian Stroke Network, which was pivotal for his future studying cerebral vascular development and disease. Mutations in COL4A1 and COL4A2 cause a multi-system syndrome and Dr. Gould’s team has won multiple grants from the American Heart Associate and National Institute for Neurological Disease and Stroke to study the cerebrovascular consequences of these mutations. They have characterized a broad spectrum of disease ranging from embryonic cerebral hemorrhages and
porencephaly to subtle, age-related cerebral vascular dysfunction that may contribute to vascular cognitive impairment.

**J Taylor Harden, PhD, RN, FGSA, FAAN** is the Founding Executive Director and director emeritus of the National Hartford Center of Gerontological Nursing Excellence, a non-profit association of 60+ schools of nursing and institutions dedicated to advancing optimal health care for older adults worldwide. She is a nurse gerontologist, having served as the assistant to the director of the National Institute on Aging in the Office of Special Populations with wide-ranging research and administrative expertise in behavioral and social sciences, clinical interventions, risk and resilience in older women, minority health and health disparities. Her research focus and advocacy are on caregivers and families from diverse and underserved populations supporting persons with dementia. Dr. Harden is serving or has served as adjunct faculty, schools of nursing at the University of Maryland, Johns Hopkins University and New York University. Dr. Harden served on the Committee on Preventing Dementia and Cognitive Impairment, The National Academies of Sciences, Engineering and Medicine and the National Advisory Council on Aging, National Institutes of Health. She is a Fellow of the Gerontological Society of America, New York Academy of Medicine and American Academy of Nursing. She received both bachelor’s and master’s degrees in nursing from the University of Maryland at Baltimore, and earned her Doctor of Philosophy in Psychiatric Mental-Health Nursing (Psycho-gerontology) from the University of Texas at Austin.

**Mark Herthel, BS** is the co-founder and CEO of Platinum Performance, Inc, a research-based therapeutic nutrition company specializing in clinical nutritional formulas for horses, dogs, cats, and people. Mark founded the company in 1996 together with his father, renowned equine veterinarian and surgeon, Dr. Doug Herthel. Dr. Herthel, a revolutionary figure in equine medicine, passed away in July 2018 from Lewy Body Dementia. Since his father’s diagnosis, Mark and the Herthel family have worked to support Lewy Body Dementia research while starting discussions between human and veterinary neurology researchers.

**Cynthia Huling Hummel, BS, MDiv, DMin** of Elmira, NY serves on National Council on Alzheimer’s Research, Care and Service. Passionate about research, she enrolled in the ADNI study and is in her 9th year. Diagnosed with MCI in 2011 and with AD in 2016, she is very active in the Rochester & Finger Lakes Chapter of the Alzheimer’s Association and is a National Early-Stage Alumna Advisor for the Alzheimer’s Association. Locally, she leads a support group and hosts social & educational activities for those living with AD/ADRD. Cynthia is an active advocate and speaks locally and nationally about living with Alzheimer’s. She sings in a country-rock band and was elected to the NY State Country Music Hall of Honor in 2016. Cynthia was named Volunteer of the Year in 2016 for starting a kayaking club and was honored in 2017 as a Rotary Club Paul Harris Fellow for her volunteer work. Cynthia is an artist and author, and her book, “UnMasking Alzheimer’s” (Lulu Press) showcases her 30 masks and her observations on living with Alzheimer’s. A life-long learner, Cynthia enrolled at Elmira College in 2011 and is currently taking her 36th class. Cynthia continues to substitute preach in small country churches in the Finger Lakes region. Alzheimer’s is her ministry- helping people move from “Why Me?” to “What Next?” As a member of the Faith United Against Alzheimer’s Coalition, Cynthia has written several chapters for an upcoming book on serving the spiritual and worship needs of persons with dementia.

**Sharon K. Inouye, MD, MPH** is Professor of Medicine at Harvard Medical School, Milton and Shirley F. Levy Family Chair, and Director of the Aging Brain Center at the Marcus Institute for Aging Research, Hebrew SeniorLife, is an internationally recognized leader in geriatric medicine and aging research. She
is an elected member of the National Academy of Medicine, chaired the Delirium Clinical Guidelines Panel for the American Geriatrics Society, and serves as an Associate Editor of the Journal of the American Geriatrics Society. Her research focuses on prevention of delirium and cognitive decline with aging, promoting healthy aging, and improvement of healthcare systems through policy. NIH-funded since 1989 with over 80 grants (>60 million) and over 300 publications, many in the highest impact journals (H-index=91), she was named by Thomson Reuters ScienceWatch as one of the World’s Most Influential Scientific Minds of the decade (2014). She developed the Confusion Assessment Method (CAM)—the most widely used method for delirium identification, used in >4000 publications and translated into 20 languages—along with the Hospital Elder Life Program (HELP) for delirium prevention, a cost-effective model of patient-centered care that has been disseminated to hundreds of hospitals worldwide. She is the Overall Principal Investigator of the SAGES study, the first funded P01 for delirium research, recently renewed, which is investigating brain vulnerability and the inter-relationship of delirium and dementia. She is committed to translating research into practice and policy changes and served as a Health and Aging Policy Fellow in Washington, D.C. from 2016-2017. She has mentored >200 trainees to date in clinical research and is a practicing clinician serving geriatric and homeless populations.

Jason Karlawish, MD is a board-certified geriatrician; professor of medicine, medical ethics and health policy and neurology at the University of Pennsylvania (Penn); co-Director of the Penn Memory Center; Director of the Outreach and Recruitment Core and Director of the Research Education Core of Penn’s NIA P30 Alzheimer’s Disease Core Center; and Director of the Penn Healthy Brain Research Center. He has substantial experience and a broad background in the diagnosis, treatment and study of older adults with cognitive impairment or at risk of cognitive impairment, particularly those with Alzheimer’s disease and other neurodegenerative diseases. His research integrates empirical, qualitative and conceptual approaches to examine the ethical, legal and social issues encountered in by older adults with cognitive impairment and their families. He uses Alzheimer’s disease and cognitive aging as models for this research. Current projects are examining the discovery and translation of Alzheimer’s disease biomarkers into clinical trials and clinical practice. He has developed processes to disclose amyloid imaging and ApoE gene results to cognitively normal older adults. He has shown how gene and biomarker knowledge creates stigma, and alters future time perspective, decision making and planning, and relationships amongst the family. This work is informed by his concept of “desktop medicine” that explains how risk has redefined disease. He developed the ACED, an instrument to assist in decisional capacity assessment, and the concept of “whealthcare,” a novel model to promote cognitive health and maintain wealth with a particular focus on the banking and financial services industries (www.whealthcare.org).

Manolis Kellis, PhD is a Professor of Computer Science at MIT, an Institute Member of the Broad Institute of MIT and Harvard, a member of the Computer Science and Artificial Intelligence Lab at MIT, and head of the MIT Computational Biology Group (compbio.mit.edu). His research spans an unusually broad spectrum of areas, including disease genetics, epigenomics, gene circuitry, non-coding RNAs, comparative genomics, and phylogenomics. He has helped direct several large-scale genomics projects, including the Roadmap Epigenomics project, the ENCODE project, the Roadmap Epigenomics Project, the Genotype Tissue-Expression (GTEx) project, and comparative genomics projects in mammals, flies, and yeast. He has mentored many students and postdocs who now hold faculty positions at Stanford, Harvard, CMU, Johns Hopkins, Sanger, UCLA, UC Davis, UC Irvine, and other top institutions. He received
the US Presidential Early Career Award in Science and Engineering (PECASE) by US President Barack Obama, the NSF CAREER award, the Alfred P. Sloan Fellowship, the Technology Review TR35 recognition, the AIT Niki Award, and the Sproolls award for the best Ph.D. thesis in computer science at MIT. He has authored over 190 journal publications, which have been cited more than 70,000 times. He lived in Greece and France before moving to the US, and he studied and conducted research at MIT, the Xerox Palo Alto Research Center, and the Cold Spring Harbor Lab. For more info, see: compbio.mit.edu and kellislab.com.

Peter T. Lansbury Jr, PhD is Chief Scientific Officer of Lysosomal Therapeutics, Inc. He graduated from Princeton University and received his PhD from Harvard University. After a postdoctoral fellowship at the Rockefeller University, he joined the faculty of the Department of Chemistry at MIT. He moved to the Harvard Medical School in 1996 and was promoted to Professor of Neurology in 2004. He was the founding director of the Morris K. Udall NIH Parkinson’s Disease Research Center of Excellence. Peter was a National Science Foundation Presidential Young Investigator and a Zenith Fellow of the Alzheimer’s Disease Association. He founded Link Medicine and served as its Chief Scientific Officer from 2005 until its sale to AstraZeneca in 2012. He is currently on leave from his position as professor of Neurology and Harvard Medical School, working at Lysosomal Therapeutics, Inc. to bring a drug to market for a genetically-defined form of Parkinson’s disease and Lewy body dementia. This compound is currently in clinical trials.

James B. Leverenz, MD is the Director of the Cleveland Lou Ruvo Center for Brain Health and the Joseph Hahn MD Endowed Chair of the Neurological Institute at the Cleveland Clinic. He obtained his undergraduate and medical education at the University of Washington. He has post-graduate training in neurology from the New York Hospital/Cornell Medical Center and neuropathology from the University of Chicago. His primary clinical and research interests are the aging-associated neurological disorders including Alzheimer’s disease, dementia with Lewy bodies, and Parkinson’s disease. Currently he is the principal investigator for the National Institute of Health funded Dementia with Lewy Body Consortium. He serves on the scientific advisory council for the Lewy Body Dementia Association and is on the board of directors and professional advisory board for the Cleveland Chapter of the Alzheimer’s Association.

Jennifer Manly, PhD is a Professor of Neuropsychology and Neurology at the G.H. Sergievsky Center and the Taub Institute for Research in Aging and Alzheimer’s disease at Columbia University. She completed her graduate training in neuropsychology at the San Diego State University / University of California at San Diego Joint Doctoral Program in Clinical Psychology. After a clinical internship at Brown University, she completed a postdoctoral fellowship at Columbia University. Her research on cognitive and genetic aspects of aging and Alzheimer’s disease among African Americans and Hispanics has been funded by the National Institute on Aging and the Alzheimer’s Association. She has authored over 160 peer-reviewed publications and eight chapters. She serves as the Chair of the Publications Committee for the International Neuropsychological Society. Dr. Manly aims to improve the diagnostic accuracy of neuropsychological tests when used to detect cognitive impairment and Alzheimer’s disease among African American and Hispanic elders. This work clarifies the independent influences of language, acculturation, educational experiences, racial socialization, and socioeconomic status on cognitive test performance, with the ultimate goal of understanding more about the relationship between culture and cognition.
**Elizabeth Rose Mayeda, PhD, MPH** is an Assistant Professor of Epidemiology at the University of California, Los Angeles (UCLA) Fielding School of Public Health. Her research focuses on identifying the origins and lifecourse mechanisms of racial, ethnic, and other social inequalities in Alzheimer’s disease-related dementias with the goal of identifying promising population-level strategies to prevent or delay onset of dementia and reduce disparities in dementia. Her work emphasizes methods to strengthen causal inference, especially tools to quantify and remediate selection bias. She is the principal investigator of a National Institute on Aging K99/R00 Pathway to Independence Award to examine the extent to which elevated blood pressure throughout adulthood contributes to racial disparities in dementia incidence. Dr. Mayeda completed her graduate training in epidemiology at the Columbia University Mailman School of Public Health and the University of California, San Francisco (UCSF). Prior to joining the faculty at UCLA, she completed a postdoctoral fellowship at UCSF.

**Luis D. Medina, PhD** is an Assistant Professor and cultural neuropsychologist at the University of Houston, where he directs the Collaborative on Aging Research and Multicultural Assessment (CARMA). He received his Ph.D. in clinical psychology/neuropsychology from the San Diego State University/University of California San Diego Joint Doctoral Program in Clinical Psychology. After completing his clinical predoctoral internship at the West Los Angeles Veterans Affairs Medical Center (geropsychology track), he completed a postdoctoral fellowship in adult clinical neuropsychology at the University of Colorado School of Medicine. As a member of the Rocky Mountain Alzheimer’s Disease Center at the University of Colorado, he performed postdoctoral research in cognitive aging and neurodegenerative disease. His research examines the cultural neuroscience of cognitive aging, particularly in the context of Alzheimer’s disease and related dementias (ADRD). Additionally, his research seeks to improve the recruitment and retention as well as the clinical assessment and diagnosis of ADRD in underrepresented populations.

**Pete Nelson MD, PhD** is an experimental neuropathologist interested in neurodegenerative diseases. The Director of the Neuropathology Division of the Pathology Department, University of Kentucky Medical Center, Pete also performs brain autopsies for the Neuropathology Core of the University of Kentucky Alzheimer’s Disease Center and directs the Alzheimer’s Disease Center’s brain bank. Following a PhD in Dr. Clifford Saper’s lab focusing on animal models of neurodegeneration, Pete was trained in neurodegenerative disease neuropathology by Dr. John Trojanowski at University of Pennsylvania. Pete’s work at the University of Kentucky has provided insights into the associative impact of pathology in the aged brain, and how genetics may play a role in neurodegenerative diseases. Pete contributed to key papers on primary age-related tauopathy (PART), age-related TDP-43 proteinopathy, and brain arteriolosclerosis. Pete also helped produce scholarship defining the neuropathologies that underlie diabetes (not Alzheimer’s disease), and the disease substrates that are associated with subjective memory complaints and mild cognitive impairments (also often not associated with Alzheimer’s disease per se!). Teasing apart the neuropathologies and genetic risk factors that characterize each AD mimicking disease provides exciting opportunities to develop new disease-modifying or disease-prevention strategies—Pete has helped move forward several clinical trials that are ongoing at the University of Kentucky to prevent ADRD based on novel mechanisms. Pete’s career is motivated partly by his own grandmother, Sylvia “Tib” Becker, who died with following a long struggle with dementia.

**Rodney Pearlman, PhD** is President of The Bluefield Project to Cure Frontotemporal Dementia. Bluefield is a non-profit foundation based in San Francisco that manages a consortium of 20 researchers...
focused on developing treatments for this devastating neurodegenerative disease. He was involved in founding several biotech companies, including Saegis Pharmaceuticals until its acquisition by H. Lundbeck A/S. Rodney was formerly Senior Vice President of Research and Development at the gene therapy company Valenti, and previously a Director of Pharmaceutical Research and Development at Genentech. At Genentech his team developed novel formulations, processes and delivery systems for a number of recombinant human proteins. He also led the Project team for Nutropin human growth hormone through its NDA approval. Rodney taught at the University of Texas in Austin and was previously a Senior Scientist with Eli Lilly and Company. Rodney received his Ph.D. in pharmaceutical chemistry from the University of Kansas in the area of delivery of drugs to the brain. He received his B. Pharm. from the Victorian College of Pharmacy, Monash University, Melbourne, Australia.

Jonathan Rohrer, MD, PhD is an MRC Clinician Scientist and Consultant Neurologist at the UCL Queen Square Institute of Neurology in London, UK. His research has focused on biomarkers in frontotemporal dementia (FTD), particularly in relation to their underlying genetic causes. Since 2011 he has been the Chief Investigator for the Genetic FTD Initiative, GENFI, an international multicentre cohort study of presymptomatic genetic FTD (www.genfi.org.uk) which has recruited 900 participants. In a collaboration between GENFI and the ARTFL/LEFFTDS study he co-leads the FTD Prevention Initiative (FPI). He has also set up FTD UK (www.ftduk.org), an annual scientific meeting of UK researchers who work in the FTD field (running since 2011), and runs a website dedicated to providing research updates to the general public about FTD: FTD talk (www.ftdtalk.org).

Jeffrey D. Rothstein MD, PhD is the John W. Griffin Director for the Brain Science Institute, as well as a Professor of Neurology and Neuroscience, and the Founding Director of the Robert Packard Center for ALS Research at Johns Hopkins University School of Medicine. He received his MD and PhD from the University of Illinois, followed by Neurology residency at Johns Hopkins University. He is a clinician scientist studying amyotrophic lateral sclerosis pathophysiology, basic and disease-based astrocyte/oligodendrogial biology and therapy discovery. His research lead to the first successful, FDA-approved drug to slow ALS and most recently in the development of antisense therapies for C9orf72 ALS/FTD. Recently he has defined the defect in nuclear transport/pores that underlie a large percentage of ALS, Huntington’s disease and Alzheimer’s dementia patients. In addition to running an ALS clinic at Johns Hopkins, he also runs the Johns Hopkins Brain Science Institute and its drug discovery group to identify novel therapeutics for neurological and psychiatric disease. He has trained over 60 graduate student, post-doctoral fellow, neurology residents, physician-scientists and junior faculty who have gone on to worldwide careers in academia, pharma industry and health care regulatory government.

Henrieta Scholtzova, MD, PhD is a Research Assistant Professor in the Department of Neurology and the Center for Cognitive Neurology at New York University Langone Medical Center. She received her MD and PhD degrees from the P.J. Safarik University, Slovakia and completed post-doctoral training in the Conformational Disorders Laboratory at New York University School of Medicine. Dr. Scholtzova’s primary area of research has focused on reducing age-related defects associated with immune cell function and ameliorating Alzheimer’s disease pathology via stimulation of innate immunity in experimental models of neurodegeneration. She is currently conducting translational research using non-human primates to determine whether stimulation of TLR9 signaling can have beneficial effects in a non-human primate model of sporadic cerebral amyloid angiopathy (CAA), squirrel monkey. She is also interested in validation of MRI methodologies in order to monitor the efficacy and safety of
immunotherapeutic interventions using non-human primates. Dr. Scholtzova is a recipient of the 2018 Alzheimer’s Association Margaret M. Cahn Research Award. Her research is currently funded by the National Institutes of Health and the Alzheimer’s Association.

Andy Shih, PhD is currently an Associate Professor at the Seattle Children’s Research Institute and in the Department of Pediatrics at the University of Washington. He obtained his Ph.D. in Neuroscience at the University of British Columbia (2006), and then completed a post-doctoral fellowship in Neurophysics at the University of California, San Diego (2012). He initiated his independent research program at the Medical University of South Carolina in the Department of Neuroscience (2012-2018), before moving to the city of Seattle. His research uses state-of-the-art in vivo imaging methods to examine the basis of neurovascular function and dysfunction in models of stroke and small vessel disease. His recent studies have focused on modeling microscopic ischemic lesions observed in VCID (cerebral microinfarcts), to understand their enduring effects and contributions to cognitive impairment. A second line of research examines microvascular pericytes and their role in maintaining vascular stability in the developing and adult brain. His research has been continually funded by the NIH (NINDS and NIA), and by Foundations such as the American Heart Association, Dana Foundation NeuroImaging Award, Alzheimer’s Association New Investigator Award, and Charleston Conference on Alzheimer’s Disease New Vision Award. Additional information can be found on his lab website: Theshihlab.com.

Sonja W. Scholz, MD, PhD obtained her MD from the Medical University Innsbruck, Austria and her PhD in Neurogenomics from the University College London, UK. She completed her neurology residency training at Johns Hopkins University, and she is a board-certified neurologist specialized in neurodegeneration. She is a Lasker Clinical Research Scholar and Investigator at the National Institute of Neurological Disorders and Stroke. Her research is focused on the molecular genetics underlying complex neurodegenerative syndromes, with a particular interest in Lewy body dementia and related parkinsonism syndromes. Her research program uses modern genomic technologies and data-driven approaches to understand the genetic determinants and pathophysiology of neurodegenerative syndromes, to identify targets for disease-modifying agents and to improve early-stage diagnostic precision. She is leading an international consortium that is performing genome sequencing of a large cohort of Lewy body dementia cases to extend modern gene discovery efforts to this underserved disease.

Dominic Sisti, PhD is director of the Scattergood Program for the Applied Ethics of Behavioral Health Care and assistant professor in the Department of Medical Ethics & Health Policy at the University of Pennsylvania. He holds secondary appointments in the Department of Psychiatry, where he directs the ethics curriculum in the residency program, and in the Department of Philosophy. Dr. Sisti’s research examines the ethics of mental health care services and policies, including long-term psychiatric care for individuals with serious mental illness and ethical challenges in correctional mental health care. He also studies how mental disorders are named, defined, and categorized.

Douglas H. Smith, MD is the Robert A. Groff Endowed Professor and Vice Chairman of Neurosurgery and he serves as Director of the Center for Brain Injury and Repair at the University of Pennsylvania. Additionally, Dr. Smith is the Scientific Director for the Big 10/ Ivy League Collaboration on Concussion and he is a member of the Scientific Advisory Boards of the US National Football League’s (NFL) the NCAA-DoD Grand Alliance CARE Consortium. For research efforts, Dr. Smith is director of several multi-center research programs on concussion and TBI-induced neurodegeneration. Dr. Smith also directs an
NIH training grant for brain injury. His group has established that diffuse axonal injury (DAI) is a key pathological feature of concussion and that the extent of acute axonal pathology is predictive of cognitive outcome. In addition, his group has discovered mechanisms of concussion and more severe TBI that lead to progressive neurodegeneration, such as chronic traumatic encephalopathy. These collective efforts are represented in over 250 published scientific reports.

**Eric Smith, MD, MPH, FRCPC, FAHA** is Associate Professor of Neurology, Radiology and Community Health Sciences at the University of Calgary, where he directs the Cognitive Neurosciences Clinic and is a member of the Calgary Stroke Program. He holds the endowed Kathy Taylor Chair in Vascular Dementia at the University of Calgary. Dr. Smith’s research uses neuroimaging to investigate the risk factors for, and consequences of, cerebral small vessel disease in healthy populations and in patients with mild cognitive impairment or cerebral amyloid angiopathy. He leads the Vascular Cognitive Impairment team of the Canadian Consortium on Neurodegeneration in Aging (Canada’s national research network for dementia) and is a consultant to the Coordinating Center of the NINDS MarkVCID biomarker consortium.

**Heather M. Snyder, PhD** is Senior Director of Medical and Scientific Operations at the Alzheimer’s Association. Dr. Snyder manages the Association's International Research Grant Program, through which the Association funds research around the world. She oversees the Association’s relationship with the leading disease journal in clinical neurology, *Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association*, and its two companion open access journals. She is responsible for implementing the Alzheimer’s Association Women’s Alzheimer’s Research Initiative and leads the Association’s efforts to understand the role of vascular factors in Alzheimer's and dementia. Dr. Snyder earned a Ph.D. from Loyola University Chicago Stritch School of Medicine, and a bachelor’s degree in Biology and Religious Studies from The University of Virginia.

**Holly D. Soares, PhD** is the head of Translational Neuroscience at AbbVie. Her group is responsible for translational development strategies supporting target engagement, patient selection and differentiation and clinical development of AbbVie neuroscience assets. Dr. Soares completed her undergraduate work at Oberlin College and went on to obtain a PhD in biomedical science from the University of Connecticut Health Center. After completing post-doctoral training at the Roche Institute of Molecular Biology, Dr. Soares served as an Assistant Professor at the Morehouse School of Medicine and then joined Pharma where she led neuroscience translational medicine initiatives at Pfizer and BMS prior to joining AbbVie. Dr. Soares has chaired the public private scientific board of the Alzheimer’s disease neuroimaging initiative and worked actively in the private and precompetitive space to enable biomarker qualification for early Alzheimer’s disease biomarkers. In addition, Dr. Soares has expertise in companion diagnostic development and developing translational plans for fibrosis and rare central nervous system (CNS) diseases. Dr. Soares is committed to the mission of developing effective therapies for patients suffering from disabling neurodegenerative disorders.

**Nadine Tatton, PhD** is the Scientific Director for the Association for Frontotemporal Degeneration (AFTD). Dr. Tatton provides oversight for AFTD’s expanding program of competitive research grants which include a postdoctoral fellowship program and pilot grants to support early career researchers, as well as the FTD Biomarkers Initiative. She provides strategic leadership for AFTD on our partner programs with the Alzheimer’s Drug Discovery Foundation (ADDF) which include TreatFTD for early phase clinical trials, Accelerating Drug Discovery for Frontotemporal Degeneration and the newly created Diagnostics Accelerator for Alzheimer’s Disease and related dementias which includes ADDF,
Gates Ventures and other partners. Dr. Tatton is lead organizer for the FTD Treatment Study Group conference which brings together international experts from industry, academia and government agencies with a focus on drug development, clinical trial design and outcome measures for FTD disorders. Dr Tatton received her PhD from the University of Toronto, Department of Physiology in 1989 and received postdoctoral fellowship awards to study with Dr. Peter Richardson at the Montreal General Hospital, Division of Neurosurgery, Montreal, Canada and with Dr. John Roder at the Samuel Lunenfeld Research Institute, Mt. Sinai Hospital, Toronto, Canada. She was an Assistant Professor in the Department of Neurology at the Mt. Sinai School of Medicine in New York where she held numerous grants and industry contracts focused on the molecular biology of neurodegeneration pathways and creating pre-clinical drug development models for Parkinson’s Disease.

**Michael Ward, MD, PhD** received his B.S. from Kenyon College in 1999 and M.D. and Ph.D. degrees from Washington University in St. Louis in 2007. As a graduate student, he worked in Yi Rao’s lab and studied the regulation of cell migration during neurodevelopment. Following a neurology residency at the University of California in San Francisco, he sub-specialized in behavioral neurology and completed a postdoctoral fellowship in Li Gan’s lab studying basic mechanisms of frontotemporal dementia. As a fellow he received an American Brain Foundation CRTF award and a NIH K08 career development award. In 2015 he joined the NINDS as an Assistant Clinical Investigator and became an Investigator in 2017. His research focuses on identifying intersecting mechanisms of neurodegenerative diseases, with an ultimate goal of developing targeted, disease-modifying therapies for affected patients.

**Daniel Weintraub, MD** is Professor of Psychiatry and Neurology at the University of Pennsylvania School of Medicine and Psychiatrist at the Parkinson’s Disease Research, Education and Clinical Center (PADRECC) at the Philadelphia Veterans Affairs (VA) Medical Center. A board-certified geriatric psychiatrist, he conducts clinical research in the psychiatric and cognitive complications of Parkinson’s disease and related disorders. He completed a NIMH Career Development Award related to depression in PD, and has been PI on grants from NIH, VA, Penn, the Fox Foundation, the International Parkinson Disease and Movement Disorder Society, and several industry-sponsored studies. He currently is former Lead of the Clinical Core of the Penn Udall Center focused on cognitive impairment in PD, and current Chair of the Cognitive-Behavioral Workgroup for the Fox Foundation-funded Parkinson’s Progression Markers Initiative and serves on the International Parkinson and Movement Disorder Society (IPMDS) Rating Scales Review Committee, Steering Committee of the Non-Motor PD Study Group, and Task Force for Parkinson’s Disease Subtypes. Dr. Weintraub also is Associate Editor of Movement Disorders Journal.

**Sandra Weintraub, PhD, ABCN/ABPP** is Professor of Psychiatry and Behavioral Sciences, Neurology and Psychology at Northwestern University Feinberg School of Medicine. She is the Clinical Core and Associate Director of the Northwestern NIA-funded Alzheimer Center in the Mesulam Center for Cognitive Neurology and Alzheimer’s Disease. She was one of the two Scientific Honorees recognized at the Rita Hayworth Gala of the Alzheimer’s Association in 1997. She served on the Alzheimer’s Disease Clinical Task Force, a special advisory committee to the NIA, to create a method for standardizing data collection at all 30+ centers funded by the NIA across the US, including specialized tests for disorders related to FTLD. She was a member of three special work groups to redefine the 2011 criteria for the clinical diagnosis of dementia of the Alzheimer type, behavioral variant frontotemporal dementia, and primary progressive aphasia. Dr. Weintraub received her bachelor’s degree from McGill University and
PhD from Boston University and was previously on the faculty at Harvard Medical School. She is board certified in Clinical Neuropsychology by the American Board of Professional Psychology. She directs the outpatient clinical neuropsychology service at the Neurobehavior and Memory Clinic of Northwestern Medicine, a multidisciplinary clinic dedicated to state-of-the-art diagnostic, treatment and research resources for patients with dementia and their caregivers. Dr. Weintraub has authored over 250 articles and book chapters on the neuropsychology of dementia and aging, aphasia and spatial attention.

Kristine Yaffe, MD attended Yale University for her undergraduate degree, received her medical degree at the University of Pennsylvania, and completed residencies in Neurology and Psychiatry at the University of California, San Francisco. She is the Scola Endowed Chair and Vice Chair and Professor of Psychiatry, Neurology, and Epidemiology at the University of California, San Francisco. She is also the Chief of NeuroPsychiatry and Director of the Memory Evaluation Clinic at the San Francisco Veterans Affairs Medical Center. In both her research, clinical work, and mentoring, she has directed her efforts towards improving the care of patients with cognitive disorders and other geriatric neuropsychiatric conditions. Dr. Yaffe’s research focuses on the epidemiology of cognitive aging. As the principal investigator of multiple grants from the NIH, Department of Defense, and several foundations, she is a leading expert in the modifiable risk factors of dementia, and she has published over 500 peer-reviewed articles (H-index=127; recognized by Clarivate Analytics as one of the most highly cited researchers in her field). Dr. Yaffe served as the Co-Chair of the United States’ Institute of Medicine’s Committee on Cognitive Aging which released a report in 2015 entitled, “Cognitive Aging: Progress in Understanding and Opportunities for Action”. She is a member of the Beeson Scientific Advisory Board and the Global Council on Brain Health. Dr. Yaffe has received several awards for her distinguished, scholarly work, including the American Association for Geriatric Psychiatry’s Distinguished Scientist Award and the American Academy of Neurology’s Potamkin Prize for Alzheimer’s Research.

Henrik Zetterberg, MD, PhD is a Professor of Neurochemistry at the University of Gothenburg, Sweden, and University College London, UK, and a Clinical Chemist at the Sahlgrenska University Hospital in Gothenburg. He is Head of the Department of Psychiatry and Neurochemistry at the University of Gothenburg, and his main research focus and clinical interest are fluid biomarkers for central nervous system diseases, Alzheimer’s disease in particular. He has published more than 900 papers and has received numerous awards.
Dining

The Natcher Conference Center has a cafeteria that is located on the main level and open from 6:30 a.m. to 2:30 p.m.; there is also a convenience store and a vending machine. An alternate full-service cafeteria is located in nearby Lister Hill Center (building 38A), and there is a large food court in the NIH Clinical Center (Building 10), which is a 5-10 minute walk from Natcher.
Portions of this event were made possible by the

with generous support from the following contributors:

Elite

Alzheimer’s Association

Platinum

GHR Foundation

Gold

Biogen

Silver

Accelerate Cure/Treatments for Alzheimer’s Disease (ACT-AD) Coalition
Alzheimer’s Drug Discovery Foundation
American Stroke Association, a division of the American Heart Association
CurePSP
EIP Pharma
The John A. Hartford Foundation
WellMed Charitable Foundation